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Sir,
Thornton and Baum (1999) advocate the establishment of a
Citizen’s Jury to provide an open and enlightened forum for
discussing the introduction of a mammography screening
programme. Yet one essential witness to their jury appears to be
missing – an investigator who looks at this potentially painful and
injurious procedure from a biological perspective.
Pain is a physiological warning sign for injury. In response to
injury, serum or wound fluid is formed to stimulate tissue repair. If
the wound is sterile, immune cytotoxic responses are not required
and only cellular regeneration is necessary. Thus, the mitogenic
properties of serum make it an excellent growth medium for
tumour cells. However, serum-stimulated tumour cell growth is
not simply an in vitro phenomenon, but occurs in vivo as well – as
demonstrated in a recent article in this journal (Abramovitch et al,
1999). The investigators examined the effect of injected wound
fluid on the growth and vascularization of implanted tumour
spheroids in nude mice. They found that wound fluid from sites of
injury was directly mitogenic to tumour cells and led to acceler-
ated tumour growth, and that such fluid may trigger ‘the angio-
genic switch of avascular, dormant microtumours’. In humans, an
association between physical injury and the subsequent develop-
ment/progression of breast and other cancers has long been
suspected (Coley, 1911).
We are concerned that the potential compressive injury resulting
from mammography could augment the growth dynamics of
dormant or slow growing tumours (van Netten et al, 1994). The
‘discomfort’ induced by mammographic compression is not trivial
(Poulos and Rickard, 1997), nor is the more vigorous compressive
follow-up performed on women with suspicious mammograms
(van Netten et al, 1997). Bruising is not an uncommon result of
this procedure (Elwood et al, 1998). Investigators should consider
that the physical pain and injury are more than just deterrents to
further screening. During compression (up to 200 N or 45 lbs), the
less dense fatty tissue will easily redistribute, however, this leaves
the brunt of compressive force on the denser tumour tissue.
Thus a procedure, which has both potential for benefit and
harm, may explain the negative findings of the recently published
analysis of the Swedish mammography programme (Sjonell and
Stahle, 1999). At the 10-year review of a programme involving
over 600 000 participants, no significant mortality reduction in
women 50–69 was observed. In theory, one would expect that the
removal of in situ and other early stage carcinomas in a significant
proportion of women would reduce mortality from this disease –
unless, simultaneously, this compressive procedure could alter the
nature of this disease by enhancing its spread and increasing its
rate of growth. Women who experience intense pain during this
procedure may be most at risk and alternatives to compressive
screening are needed. We predict that such a screening programme
will have a significant effect on mortality reduction. Furthermore,
modern epidemiological studies examining the association
between injury and subsequent malignant progression are required
to elucidate how trauma may act as a co-carcinogen.
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Sir,
Those who organize a Citizens’ Jury have considerable power and
responsibility. Not only are they required to select the witnesses
but they have to brief the jury, organize the presentation of the
information, moderate on the proceedings and report on the find-
ings.
It is thus important that organizers commissioned to arrange this
democratic way of examining important questions enabling people
to exercise their citizenship, recognize their accountability both to
the sponsors and the public. They must be open and fair in all the
aspects listed above. Consideration of selection of witnesses, both
those who volunteer and those to be invited, must allow for as
wide and balanced a spectrum of considerations as possible so that
a representative cross-section of opinion is provided. This presen-
tation of evidence then offers some chance of a fair verdict being
decided by 12 (or more!) good men and true.Letters to the Editor 1427
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We are therefore pleased that our suggestion has resulted in the
first volunteer. Our list of witnesses was not intended to be exhaus-
tive, final or complete: only to stimulate consideration of this
democratic method and elicit constructive suggestions.
H Thornton and M Baum
Prognostic value of cathepsin D in breast cancer
Sir
A recent publication in this journal demonstrated, that cathepsin D
was an independent marker of poor prognosis in 2810 breast
cancer patients (Foekens et al, 1999). A covering editorial rose
questions on the still unexplained biological role of cathepsin D in
breast cancer (Westley et al, 1999). Cathepsin D levels correlated
with increasing invasiveness and high metastatic potential of
tumour cells in breast cancer. Breast cancer cells were found to
secrete cathepsin D into the cell culture medium. Thus, it is
commonly hypothesized, that cathepsin D might be involved in the
extracellular breakdown of the tumour stroma in vivo and
contribute to tumour dissemination. This hypothesis needs
comment and should be modified in view of recent findings. High
cathepsin D levels are not only present in breast cancer samples,
but have been described for a multitude of other tumour entities,
such as laryngeal cancer, cancers of the head and neck, ovarian
cancer, endometrial cancer, bladder cancer, or in malignant
glioma. In these reports, high cathepsin D levels were usually also
considered as a sign of a poor prognosis. High levels of other lyso-
somal cathepsins B, H and L have been detected in a variety of
different cancers including breast cancer, as well (Recklies et al,
1980). These observations clearly indicate that a highly active
lysosomal system is characteristic of cancer tissue.
Lysosomes are involved in the degradation of extracellular
material ingested by endocytosis. Cathepsins are intralysosomally
active at pH 3–5 and loose most activity at a neutral pH (Bohley et
al, 1992). Although cathepsin D might be secreted by cancer cells,
there is no evidence available that the secreted enzyme is actively
involved in the extracellular degradation of the extracellular
matrix (ECM) at the neutral or slightly acidic pH in tumour tissues
in vivo. In cell culture, extracellular degradation of ECM mediated
by cathepsin D was only achieved after lowering the pH to 4.5 in
the cell culture media, but not at pH 7.4 (Briozzo et al, 1988).
When invasiveness of breast cancer cells was studied in the
Boyden chamber, the secretion of cathepsin D even correlated
inversely with the aggressive behaviour of the cancer cells
(Johnson et al, 1993). To our knowledge extracellular acidic
compartments containing proteases of lysosomal origin involved
in a break-down of ECM, have not been found in tumour tissues.
In contrast, there are a variety of other formidable proteases
available, which are responsible for extracellular proteolysis of the
ECM (recently reviewed by Price et al, 1997). All of these are
active at a neutral pH, and highly regulated by their respective
inhibitors. These proteases belong to the plasminogen activator
(PA) or to the matrix metalloproteinase (MMP) superfamilies.
Increased expression of PA and MMPs in a variety of tumours,
including breast cancer, are associated with a high metastatic
potential and poor prognosis (Stetler Stevenson et al, 1996; Duffy
et al, 1998). Invasive cells form specialized membrane protru-
sions, called invadopodia, that actively degrade the surrounding
ECM (Kelly et al, 1994). MMPs are structurally and functionally
linked with invadopodia (Chen, 1996; Nakahara et al, 1997). To
our knowledge there are no reports on cathepsin activity in
connection to invadopodia so far.
Instead, considerable evidence points to an important role for
cathepsins as proteolytic enzymes in the lysosomal system.
Invasive breast cancer cells were able to ingest considerable
amounts of extracellular material in large acid phagosomes (pH <
4). The presence of these phagosomes coincided with an increased
ability of these cells to migrate through matrigel, and with high
cathepsin D levels (Montcourrier et al, 1990, 1994). Recent data
support these observations, indicating that MMPs were respon-
sible for the partial degradation of a cross-linked gelatine matrix.
The gelatin fragments were taken up by phagocytosis and destined
to lysosomes for further degradation. This phagocytic capacity of
breast cancer cells was directly linked to their invasiveness
(Coopman et al, 1998).
Further observations strengthen the concept of an active lyso-
somal digestive system and hence high cathepsin D levels in
malignant tumours. Tumours have been termed nitrogen traps.
During tumour cell proliferation extensive amounts of nitrogenous
substrates are required to provide material for cell duplication
(new tumour proteins, DNA, RNA …). Free amino acid concen-
trations in blood are low, leaving only plasma proteins (mostly
albumin) as the major external source for additional nitrogen,
necessary during tumour proliferation (Stehle et al, 1997). And
indeed, there are reports confirming albumin accumulation and
degradation in tumours (Sinn et al, 1990; Andersson et al, 1991;
Wunder et al, 1997). In sarcoma-bearing mice the intralysosomal
accumulation of residualizingly radiolabelled albumin was three-
fold higher in tumour tissue compared to liver tissue. Accounting
for the entire tumour the proteolytic capacity for albumin break-
down exceeded that of the healthy liver by a factor of five
(Andersson et al, 1991). Interestingly, cathepsin D is closely
involved in the lysosomal catabolism of albumin (Mego, 1984). A
considerably increased intracellular albumin content was found in
an immunohistological study of breast cancer tissue (Vercelli Retta
et al, 1987). High plasma protein (albumin) accumulation was also
detected in homogenized tumour tissue from mastectomy speci-
mens. A significant correlation between high plasma protein
content in the samples and poor prognosis in breast cancer patients
was established (Soreide et al, 1991a, 1991b).
ECM fragments and plasma proteins have been identified as
substrates for lysosomal cathepsins. Tumour cell apoptosis might1428 Letters to the Editor
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provide further material doomed for lysosomal digestion. Tumours
have a high rate of cell turnover, and e.g. the cell loss was estab-
lished as high as 96% (Refsum et al, 1967). Remnants of apoptotic
cells might be recognized and rapidly phagocytosed by neigh-
bouring cells in the tissue (Collins et al, 1993). A high apoptotic
index in breast cancer cells was associated with a high mitotic rate,
tumour necrosis, dense stromal lymphocyte infiltration, lack of
tubule formation, lack of sex steroid receptor expression, a high
grade tumour and with a short recurrence free survival (Lipponen
et al, 1994). In addition, macrophages might also be involved in
the phagocytosis of apoptotic cells (Savill et al, 1993). The role of
macrophages, leucocytes, fibroblasts or of neighbouring tumour
cells in the clearance and degradation of apoptotic cell remnants
still remain to be further clarified. Interestingly, high cathepsin D
levels also coincide with all of these cell types present in breast
cancer tissue.
Based on these observations, we conclude that the biological
role of cathepsin D is mostly confined to the lysosomal system.
High cathepsin D levels in tumour tissues reflect high lysosomal
turnover. This turnover is likely to be caused by an increased
uptake and digestion of ECM fragments, of plasma proteins, and
of cellular debris (remnants of apoptotic cells?) mostly by prolifer-
ating cancer cells. The ingested and degraded materials might
serve as tumour cell nutrients. A positive correlation of cathepsin
D with tumour malignancy or metastatic potential is obvious. It is
evident, that further research is needed to investigate the role of the
lysosomal system during tumour cell proliferation.
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